GALAPAGOS NV (GXE.DE) Fundamental Analysis & Valuation

FRA:GXE • BE0003818359

Current stock price

24.38 EUR
-0.18 (-0.73%)
Last:

This GXE.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. GXE.DE Profitability Analysis

1.1 Basic Checks

  • In the past year GXE was profitable.
  • GXE had a negative operating cash flow in the past year.
  • In multiple years GXE reported negative net income over the last 5 years.
  • GXE had a negative operating cash flow in each of the past 5 years.
GXE.DE Yearly Net Income VS EBIT VS OCF VS FCFGXE.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

1.2 Ratios

  • The Return On Assets of GXE (9.42%) is better than 82.14% of its industry peers.
  • Looking at the Return On Equity, with a value of 9.92%, GXE is in the better half of the industry, outperforming 77.38% of the companies in the same industry.
  • The Return On Invested Capital of GXE (11.32%) is better than 83.33% of its industry peers.
Industry RankSector Rank
ROA 9.42%
ROE 9.92%
ROIC 11.32%
ROA(3y)5.36%
ROA(5y)1.9%
ROE(3y)6.68%
ROE(5y)1.5%
ROIC(3y)N/A
ROIC(5y)N/A
GXE.DE Yearly ROA, ROE, ROICGXE.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 -10

1.3 Margins

  • With an excellent Profit Margin value of 28.85%, GXE belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 47.04%, GXE belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 97.33%, GXE belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
  • GXE's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 47.04%
PM (TTM) 28.85%
GM 97.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
GXE.DE Yearly Profit, Operating, Gross MarginsGXE.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 150

7

2. GXE.DE Health Analysis

2.1 Basic Checks

  • GXE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • GXE has about the same amout of shares outstanding than it did 1 year ago.
  • GXE has more shares outstanding than it did 5 years ago.
  • GXE has a better debt/assets ratio than last year.
GXE.DE Yearly Shares OutstandingGXE.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
GXE.DE Yearly Total Debt VS Total AssetsGXE.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • GXE has an Altman-Z score of 7.60. This indicates that GXE is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of GXE (7.60) is better than 80.95% of its industry peers.
  • GXE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • GXE's Debt to Equity ratio of 0.00 is amongst the best of the industry. GXE outperforms 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.6
ROIC/WACC1.43
WACC7.91%
GXE.DE Yearly LT Debt VS Equity VS FCFGXE.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 20.15 indicates that GXE has no problem at all paying its short term obligations.
  • GXE's Current ratio of 20.15 is amongst the best of the industry. GXE outperforms 97.62% of its industry peers.
  • GXE has a Quick Ratio of 20.00. This indicates that GXE is financially healthy and has no problem in meeting its short term obligations.
  • GXE has a better Quick ratio (20.00) than 97.62% of its industry peers.
Industry RankSector Rank
Current Ratio 20.15
Quick Ratio 20
GXE.DE Yearly Current Assets VS Current LiabilitesGXE.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

4

3. GXE.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 334.82% over the past year.
  • The Revenue has grown by 280.53% in the past year. This is a very strong growth!
  • GXE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.97% yearly.
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.22%

3.2 Future

  • The Earnings Per Share is expected to decrease by -25.26% on average over the next years. This is quite bad
  • GXE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -30.71% yearly.
EPS Next Y-141.18%
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
EPS Next 5Y-25.26%
Revenue Next Year0.26%
Revenue Next 2Y-2.91%
Revenue Next 3Y-9.92%
Revenue Next 5Y-30.71%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GXE.DE Yearly Revenue VS EstimatesGXE.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
GXE.DE Yearly EPS VS EstimatesGXE.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4

2

4. GXE.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 5.01, the valuation of GXE can be described as very cheap.
  • GXE's Price/Earnings ratio is rather cheap when compared to the industry. GXE is cheaper than 95.24% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.34, GXE is valued rather cheaply.
  • GXE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 5.01
Fwd PE N/A
GXE.DE Price Earnings VS Forward Price EarningsGXE.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -7.42
GXE.DE Per share dataGXE.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • A cheap valuation may be justified as GXE's earnings are expected to decrease with -45.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%

0

5. GXE.DE Dividend Analysis

5.1 Amount

  • GXE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

GXE.DE Fundamentals: All Metrics, Ratios and Statistics

GALAPAGOS NV

FRA:GXE (4/10/2026, 7:00:00 PM)

24.38

-0.18 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners25.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.61B
Revenue(TTM)1.11B
Net Income(TTM)320.88M
Analysts52.22
Price Target30.22 (23.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9817.73%
Min EPS beat(2)-19965.4%
Max EPS beat(2)329.9%
EPS beat(4)1
Avg EPS beat(4)-5598.11%
Min EPS beat(4)-19965.4%
Max EPS beat(4)329.9%
EPS beat(8)4
Avg EPS beat(8)-2634.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)487.56%
Min Revenue beat(2)-2.86%
Max Revenue beat(2)977.98%
Revenue beat(4)2
Avg Revenue beat(4)242.3%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)977.98%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.62%
PT rev (3m)-1.68%
EPS NQ rev (1m)-16.45%
EPS NQ rev (3m)-16.45%
EPS NY rev (1m)18.36%
EPS NY rev (3m)-9.64%
Revenue NQ rev (1m)-0.4%
Revenue NQ rev (3m)-0.4%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)-0.19%
Valuation
Industry RankSector Rank
PE 5.01
Fwd PE N/A
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA -7.42
EPS(TTM)4.87
EY19.98%
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-4.12
FCFYN/A
OCF(TTM)-3.91
OCFYN/A
SpS16.88
BVpS49.1
TBVpS49.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number73.35
Profitability
Industry RankSector Rank
ROA 9.42%
ROE 9.92%
ROCE 16.08%
ROIC 11.32%
ROICexc 144.09%
ROICexgc 144.57%
OM 47.04%
PM (TTM) 28.85%
GM 97.33%
FCFM N/A
ROA(3y)5.36%
ROA(5y)1.9%
ROE(3y)6.68%
ROE(5y)1.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.01
Cap/Depr 24.8%
Cap/Sales 1.25%
Interest Coverage 1127.48
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.15
Quick Ratio 20
Altman-Z 7.6
F-Score6
WACC7.91%
ROIC/WACC1.43
Cap/Depr(3y)83.14%
Cap/Depr(5y)94.58%
Cap/Sales(3y)13.02%
Cap/Sales(5y)12.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
EPS Next Y-141.18%
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
EPS Next 5Y-25.26%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.22%
Revenue Next Year0.26%
Revenue Next 2Y-2.91%
Revenue Next 3Y-9.92%
Revenue Next 5Y-30.71%
EBIT growth 1Y377.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.82%
EBIT Next 3Y8.25%
EBIT Next 5Y15.02%
FCF growth 1Y32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.55%
OCF growth 3YN/A
OCF growth 5YN/A

GALAPAGOS NV / GXE.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GALAPAGOS NV (GXE.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to GXE.DE.


What is the valuation status for GXE stock?

ChartMill assigns a valuation rating of 2 / 10 to GALAPAGOS NV (GXE.DE). This can be considered as Overvalued.


How profitable is GALAPAGOS NV (GXE.DE) stock?

GALAPAGOS NV (GXE.DE) has a profitability rating of 5 / 10.


What are the PE and PB ratios of GALAPAGOS NV (GXE.DE) stock?

The Price/Earnings (PE) ratio for GALAPAGOS NV (GXE.DE) is 5.01 and the Price/Book (PB) ratio is 0.5.